Results 31 to 40 of about 832,259 (254)

2B4 co-stimulation and dasatinib modulation enhance anti-CD19 CAR-NK-92 cell cytotoxicity

Frontiers in Immunology
IntroductionChimeric Antigen Receptor (CAR)–based therapies have transformed cancer treatment, especially in hematological malignancies. While the impact of co-stimulatory domains on CAR-T cell efficacy is well established, the optimal signaling modules ...
Matheus Henrique dos Santos, Júlia Teixeira Cottas de Azevedo, Mara Elisama da Silva Januário, Dayane de Fátima Schmidt, Mariane Cariati Tirapelle, Alison Felipe Bordini Biggi, Sima Ebrahimabadi, Renata Nacasaki Silvestre, Dimas Tadeu Covas, Rodrigo T. Calado, Rodrigo T. Calado, Virgínia Picanço-Castro   +11 more
doaj   +1 more source

Células asesinas naturales con el receptor de antígeno quimérico (CAR-NK): terapia emergente contra el cáncer

, 2021
One of the novel and effective devices against leukemia and solid tumors in adoptive immunotherapies is the use of the chimeric antigen receptor “CAR”.
Vázquez Rodríguez , Adrián, Mendoza-Rincón, Jorge Flavio, Jorge Flavio Mendoza-Rincón, Adrián Vázquez Rodríguez, Vázquez Rodríguez, Adrián   +4 more
core   +2 more sources

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy

Experimental Hematology & Oncology
Chimeric antigen receptor (CAR)-NK therapy holds great potential for tumor treatment, but current CAR designs are primarily optimized for T cells, raising concerns about their suitability for NK cells. This study compared two dominant CAR designs used in
Pengchao Zhang, Xuejia Feng, Xiangyun Niu, Zhongming Liu, Minghui Li, Maoxuan Liu, Dehong Yan, Guizhong Zhang, Xiaochun Wan   +8 more
doaj   +1 more source

Constitutive IL-7 signaling promotes CAR-NK cell survival in the solid tumor microenvironment but impairs tumor control

Journal for ImmunoTherapy of Cancer
Background Adoptive transfer of chimeric antigen receptor (CAR)-expressing natural killer (NK) cells has demonstrated success against hematological malignancies.
Robin Parihar, Cliona M Rooney, Matthew Dysthe, Ishwar Navin, Corrine Baumgartner, Dayenne van Leeuwen, Josue Pineda   +6 more
doaj   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways

Experimental Hematology & Oncology
Background NK cells engineered to express interleukin-15 (IL-15) and a CD19-targeted chimeric antigen receptor (CAR) have been used to treat patients with relapsed and/or refractory B cell malignances, demonstrating encouraging outcomes and favorable ...
Bailin He, Hong Chen, Jiaxu Wu, Shiqiu Qiu, Qiusui Mai, Qing Zeng, Cong Wang, Shikai Deng, Zihong Cai, Xiaoli Liu, Li Xuan, Chengyao Li, Hongsheng Zhou, Qifa Liu, Na Xu   +14 more
doaj   +1 more source

An Integrated Oxygen‐Supplying Device and Predictive Multiphysics Model for Extended Ambient Transport of Insulin‐Producing Cells

Advanced Functional Materials, EarlyView.
Cell therapies typically rely on cold‐chain logistics and cryopreservation, limiting access and compromising cell quality. Here, a dual‐chamber device separates an oxygen‐supplying chamber from a hyaluronic acid cargo chamber, sustaining oxygen delivery for over 70 h and enabling ambient‐temperature shipment.
Daniel A. Domingo‐Lopez, Ruth Tarpey, Benjamin Brennan, Bryan D. Boyle, Amir M. Alsharabasy, Abhik Mallick, Gabriella Bellavia, Abhay Pandit, Garry P. Duffy, Ruth E. Levey   +9 more
wiley   +1 more source

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges

Frontiers in Immunology
Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a novel immunotherapy targeting cancer cells via the generation of chimeric antigen receptors on NK cells which recognize specific cancer antigens. CAR-NK cell therapy is gaining attention
Jun Chang Kong, Mohammad Auwal Sa’ad, Mohammad Auwal Sa’ad, Hema Manusri Vijayan, Manickam Ravichandran, Manickam Ravichandran, Venugopal Balakrishnan, Seng Kong Tham, Gee Jun Tye   +8 more
doaj   +1 more source

Topically Delivered Treg‐Attracting Microparticle‐Hydrogel Composites Recruit Regulatory T Cells and Limit Cardiac Injury After Severe Ischemia

Advanced Healthcare Materials, EarlyView.
CCL22‐releasing PLGA microparticles (MP) suspended in topically applied hydrogels (HEART) establish a sustained chemokine gradient at the injured myocardium. HEART recruits CCR4+ regulatory T cells, reduces infarct size and graft fibrosis, and improves cardiac function.
Matthew A. Borrelli, Alexis T. Reese, Jordan J. P. Warunek, Betsy Ann Varghese, Canxing Lin, Jeffery J. Baust, Brenda McMahon, Steven R. Little, Hēth R. Turnquist   +8 more
wiley   +1 more source